Comparison of Venetoclax‐Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single‐Center Real‐World Experience
eJHaem · 2026-06 · 7 (3)
DOI: 10.1002/jha2.70280 ↗Kurz gefasst
Fachartikel in der Zeitschrift eJHaem, online erschienen am 18.06.2026. Verfasst von Benjamin Heyman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Regenerative Medicine Department of Medicine UC San Diego Moores Cancer Center UC San Diego La Jolla California USA. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
The optimal venetoclax‐based treatment for patients with relapsed/refractory (R/R) CLL is still unknown, especially for high‐risk patients.
Methods
We performed a retrospective analysis of 98 patients with R/R CLL treated with venetoclax‐based regimens. Patients received venetoclax alone or in combination with rituximab (VenR), obinutuzumab (VenO), or a BTKi (primarily ibrutinib).
Results
Combination groups achieved higher complete remission (CR) and uMRD rates: VenO (CR 68%, uMRD 86%), VenR (CR 63%, uMRD 82%), Ven + BTKi (CR 43%, uMRD 70%), versus monotherapy (CR 51%, uMRD 67%). At a median 52‐month follow‐up, median PFS was superior in combination arms (76.6 months) compared to monotherapy (58.9 months, p = 0.04).
Conclusion
This analysis validates, in a real‐world academic cohort, that venetoclax‐based combination therapy, particularly with obinutuzumab or BTKi, yields higher rates of deep remission and superior PFS compared to monotherapy for R/R CLL.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Regenerative Medicine Department of Medicine UC San Diego Moores Cancer Center UC San Diego La Jolla California USA.
- Division of Hematology/Oncology Department of Medicine UC San Diego La Jolla California USA.
- Center for Novel Therapeutics Division of Hematology/Oncology Department of Medicine UC San Diego La Jolla California USA.
ORCID-Profile: Benjamin Heyman
Zitieren
APA
Heyman, B., Choi, M., & Kipps, T. J. (2026). Comparison of Venetoclax‐Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single‐Center Real‐World Experience. eJHaem, 7(3). https://doi.org/10.1002/jha2.70280
Vancouver
Heyman B, Choi M, Kipps TJ. Comparison of Venetoclax‐Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single‐Center Real‐World Experience. eJHaem. 2026;7(3). doi:10.1002/jha2.70280
BibTeX
@article{Heyman2026,
author = {Heyman, Benjamin and Choi, Michael and Kipps, Thomas J},
title = {Comparison of Venetoclax‐Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single‐Center Real‐World Experience},
journal = {eJHaem},
year = {2026},
volume = {7},
number = {3},
doi = {10.1002/jha2.70280}
}
EUVIMED